Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Degree programmes
  • Modules
  • Jobs
  • People
  • Research Outputs
  • Academic units
  • Third Mission
  • Projects
  • Skills

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Degree programmes
  • Modules
  • Jobs
  • People
  • Research Outputs
  • Academic units
  • Third Mission
  • Projects
  • Skills
  1. Research Outputs

Role of the HLA class II: HCV-related disorders

Academic Article
Publication Date:
2007
Short description:
Role of the HLA class II: HCV-related disorders / De Re, V; Caggiari, L; Simula, Mp; De Vita, S; Mazzaro, C; Lenzi, M; Massimo, Gm; Monti, G; Ferri, Clodoveo; Zignego, Al; Gabrielli, A; Sansonno, D; Dammacco, F; Libra, M; Sacchi, N; Talamini, R; Spina, M; Tirelli, U; Cannizzaro, R; Dolcetti, R.. - In: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. - ISSN 0077-8923. - STAMPA. - 1107:(2007), pp. 308-318. [10.1196/annals.1381.033]
abstract:
The paper highlights the role of different HLA class II molecules in hepatic and lymphoproliferative HCV-related disorders. HLA molecules have been reviewed, according to an in silico cluster classification, based on the sequence, the biochemical structure of the pockets, and the functional characteristics of the HLA II molecules. Thus, by reducing the complexity of HLA II polymorphism, characteristics that unite different HLA molecules with specific HCV-associated pathologies may be recognized with greater case. Results show that HLA clusters associated with better dlimination of the virus are protective against HCC development, while the same clusters are associated with a higher risk of developing cryoglobulinemic syndrome and the concomitant NHL. These data added further acknowledgements on pathogenetic mechanisms associated with HCV infection. Results also highlight differences of NHL occurring in HCV-positive subjects, with or without a concomitant type II autoimmune cryoglobulinemic syndrome, suggesting that cryoglobulinemic background associated with NHL should be considered in the evaluation of the effectiveness of new therapies in the course of HCV-associated NHLs.
Iris type:
Articolo su rivista
Keywords:
HLA class II; HCV-related disorders
List of contributors:
De Re, V; Caggiari, L; Simula, Mp; De Vita, S; Mazzaro, C; Lenzi, M; Massimo, Gm; Monti, G; Ferri, Clodoveo; Zignego, Al; Gabrielli, A; Sansonno, D; Dammacco, F; Libra, M; Sacchi, N; Talamini, R; Spina, M; Tirelli, U; Cannizzaro, R; Dolcetti, R.
Authors of the University:
FERRI Clodoveo
Handle:
https://iris.unimore.it/handle/11380/609334
Published in:
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.4.5.0